Navigation Links
Halozyme Secures Additional $20 Million Term Loan

SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it secured an additional $20 million loan from Oxford Finance and Silicon Valley Bank.  On December 27, 2013, Halozyme entered into an Amended and Restated Loan and Security Agreement, extending the original $30 million term loan and providing for an additional $20 million term loan, bringing the total loan balance to $50 million.  The term loan was fully drawn at close on December 27, 2013 and has a maturity date of January 1, 2018.  The proceeds will be used for working capital and other near-term growth initiatives.  Additional details of the credit facility are outlined in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 3, 2014.  As of December 31, 2013, Halozyme had approximately $71 million in cash and cash equivalents.


About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at and follow us on Twitter @HALOTherapeutic.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the use of cash from its additional term loan) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2013.

Investor Contact:
Schond Greenway
Halozyme Therapeutics

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics
2. Halozyme Therapeutics Announces Executive Transitions
3. Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
4. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
5. Halozyme to Host Third Quarter 2013 Financial Results Conference Call
6. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
7. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
8. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
9. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
10. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
11. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015  AccuTEC Blades, ... a new corporate logo and brand identity program. ... design and engineering of bladed products where "the ... --> --> Serving manufacturers and ... and auto glass equipment, AccuTEC,s product lines include ...
(Date:12/1/2015)... of adjunctive metformin therapy does not improve glycemic outcomes in ... from T1D Exchange and funded by the ... measures of obesity, including weight and BMI. The results, published ... American Medical Association , are from the largest clinical trial ... obese adolescents with type 1 diabetes. recent ...
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... , ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based ... sale in the United States. Clarity is a Superior Dual Wavelength Platform which ... a single platform that is easy to own and operate. , For over ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, “ ... a main “pain point” for merging or aligning healthcare provider organizations—when mergers and ... signed. This quick-read guidance suggests that failing to recognize the power of ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech North ... Gary has spent a significant amount of time in Sweden since joining PartnerTech ...
Breaking Medicine News(10 mins):